# Patient-Trial Match Report

*Generated: 2026-01-05 18:34:11*

## Patient Profile

- **Age**: 59
- **Sex**: Female
- **Cancer Type**: renal cell carcinoma

**Clinical Description**:
> 59-year-old female with metastatic clear cell renal cell carcinoma, status post nephrectomy (2022). First-line ipilimumab/nivolumab x4 induction then nivolumab maintenance - initial PR but progressed at 14 months. Second-line cabozantinib with mixed response, discontinued for grade 3 hand-foot syndrome and fatigue. Switched to lenvatinib/everolimus - progression at 6 months with new pulmonary and hepatic metastases. IMDC intermediate risk. Seeking novel approaches beyond standard IO/TKI combinations. HIF-2Î± inhibitors of interest. Labs show mild hyperbilirubinemia (1.4), otherwise WNL.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 4
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 52
- **LLM scored**: 48

## ðŸŸ¢ HIGH Likelihood (16 trials)

### [NCT05155033](https://clinicaltrials.gov/study/NCT05155033)

**Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic renal cell carcinoma (clear cell histology) and is refractory to anti-PD-1 therapy.
- Patient has measurable disease as per RECIST v1.1 criteria.
- Patient is aged 59 years.
- Patient has an ECOG status of 1.
- Patient is co-enrolled on protocol 03-C-0277.

**? Uncertainties:**
- Serostatus for HIV, hepatitis B, and hepatitis C is not provided. Need confirmation on these serologies.
- Organ function labs are not fully detailed; particularly creatinine level is unknown.

**Assessment:**
> The patient's cancer type (metastatic renal cell carcinoma with clear cell histology) fits the trial's eligibility criteria. The patient has also received prior PD-1 therapy and falls within the acceptable age and ECOG status. While some serological status and organ function details are missing, the critical eligibility criteria are satisfied.

---

### [NCT07077083](https://clinicaltrials.gov/study/NCT07077083)

**A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.**

- **Sponsor**: Massachusetts General Hospital
- **Phase**: Phase 2
- **Status**: Not yet recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has clear cell renal cell carcinoma (ccRCC), which matches the trial target indication.
- Patient is 59 years old, meeting the age criterion.
- ECOG status is 1, which is acceptable for eligibility.
- No brain metastases present, which is required for inclusion.

**? Uncertainties:**
- Mild hyperbilirubinemia (1.4) noted, but specific organ function details regarding eGFR are not provided.

**Assessment:**
> The patient clearly meets the disease indication as they have clear cell renal cell carcinoma, and their age and ECOG status are within acceptable ranges. The only uncertainty lies in the organ function with the absence of specific eGFR details.

---

### [NCT05433142](https://clinicaltrials.gov/study/NCT05433142)

**A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma**

- **Sponsor**: Xencor, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has clear cell renal cell carcinoma which matches the trial's studied condition.
- Patient has a current ECOG status of 1, which meets the trial's criteria.
- Patient has measurable disease and evidence of disease progression on standard-of-care therapies.
- Patient is seeking novel approaches after multiple prior therapies.

**? Uncertainties:**
- Adequate tumor sample availability is not confirmed.

**Assessment:**
> The patient has clear cell renal cell carcinoma, which aligns with the trial's conditions. The patient's ECOG status is acceptable, and she has evidence of disease progression on prior treatments. The only uncertainty is whether an adequate tumor sample is available, but this is not enough to change the likelihood of eligibility significantly.

---

### [NCT03682289](https://clinicaltrials.gov/study/NCT03682289)

**Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies**

- **Sponsor**: Rahul Aggarwal
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 59
- Sex: female
- Cancer type: renal cell carcinoma (clear cell histology)
- ECOG status: 1
- Prior therapies: ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus
- No brain metastases
- Co-mutations: VHL loss
- Country: United States
- Measurable disease by RECIST 1.1
- IMDC intermediate risk

**? Uncertainties:**
- Archival tumor tissue evaluable for biomarker testing not confirmed
- Organ function lab values are not provided

**Assessment:**
> The patient's cancer type is metastatic clear cell renal cell carcinoma which is the primary target for this trial. The patient has received multiple prior therapies, aligning with the trial's enrollment criteria for previously treated patients. Although some organ function lab results are not provided, the patient has an ECOG status of 1 and no brain metastases, which strongly supports eligibility.

---

### [NCT06265285](https://clinicaltrials.gov/study/NCT06265285)

**Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 59 (â‰¥ 18 years)
- ECOG status: 1 (acceptable PS)
- Cancer type: renal cell carcinoma (eligible condition for the trial)
- Prior treatments: received anti-angiogenic therapy as required

**? Uncertainties:**
- Labs for AST and ALT not provided
- Serum creatinine value not provided
- Exact distance from clinic not verified

**Assessment:**
> The patient's cancer type matches the trial's inclusion criteria for renal cell carcinoma, and she meets the minimum age and ECOG performance status requirements. The patient has received prior anti-angiogenic therapies, which aligns with the trial's eligibility for previously treated patients. There are some uncertainties related to lab values and distance from the clinic, but overall, the eligibility is strong.

---

### [NCT06863311](https://clinicaltrials.gov/study/NCT06863311)

**EXACT: Randomized Phase II Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC**

- **Sponsor**: Karie Runcie
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years at the time of consent.
- ECOG Performance Status of 1.
- Advanced or metastatic RCC with a clear cell component.
- Prior treatment with anti-PD-1 (ipilimumab/nivolumab) and experienced disease progression.
- No brain metastases.
- IMDC intermediate risk.

**? Uncertainties:**
- Organ function labs are not explicitly provided for eligibility confirmation.

**Assessment:**
> The patient's cancer type is clear cell renal cell carcinoma which matches the trial study conditions. The patient has progressed after treatment with an anti-PD-1 therapy, which is required for eligibility. The ECOG status and age meet the criteria, and there are no brain metastases. While organ function lab results are unspecified, the patient's profile aligns well with the trial requirements.

---

### [NCT00001238](https://clinicaltrials.gov/study/NCT00001238)

**Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has clear cell renal carcinoma which is included in the trial conditions studied
- Patient has a known VHL loss which matches the inclusion criteria for germline urologic malignancy

**Assessment:**
> The patient's cancer type matches the trial's focus on clear cell renal carcinoma, and they possess the known VHL loss mutation that qualifies them under the inclusion criteria for inherited urologic malignancies. There are no conflicting points, and all major eligibility criteria are satisfied.

---

### [NCT06332755](https://clinicaltrials.gov/study/NCT06332755)

**A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)**

- **Sponsor**: LG Chem
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age >= 18 years
- ECOG status of 1
- Cancer type is renal cell carcinoma (RCC)
- Prior therapies include treatment post previous standard therapies
- Mild hyperbilirubinemia but otherwise within normal limits

**? Uncertainties:**
- Adequate organ function details not provided
- Further details on life expectancy not explicitly stated

**Assessment:**
> The patient's cancer type of renal cell carcinoma matches the indication for the trial. The patient has previously been treated, aligning with the phase 1a criteria, which allows previously treated patients. The ECOG status is acceptable. The primary uncertainties relate to the specifics of organ function and life expectancy.

---

### [NCT06242470](https://clinicaltrials.gov/study/NCT06242470)

**A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors**

- **Sponsor**: MacroGenics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has clear cell renal cell carcinoma, which matches the trial's eligibility on cancer type.
- Patient is 59 years old, above the minimum age requirement of 18.
- Patient's ECOG status is 1, which is acceptable.
- Patient has unresectable metastatic disease.
- Patient has adequate performance status.
- Labs show mild hyperbilirubinemia but are otherwise within normal limits.

**? Uncertainties:**
- Patient's specific measurable disease status under RECIST v1.1 is not explicitly stated.

**Assessment:**
> The patient has a matching cancer type (clear cell renal cell carcinoma) for the trial and meets the age and ECOG status requirements. There is no mention of brain metastases or complications that would conflict with eligibility. The main uncertainty pertains to confirming measurable disease status based on RECIST v1.1.

---

### [NCT06222593](https://clinicaltrials.gov/study/NCT06222593)

**A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma**

- **Sponsor**: State University of New York at Buffalo
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has renal cell carcinoma, which matches the trial's conditions studied.
- Patient's ECOG status is 1, which is within the acceptable range.
- Patient has measurable disease as they have measurable metastatic clear cell renal cell carcinoma.
- The patient has a life expectancy of at least 6 months based on their current condition.

**? Uncertainties:**
- Specific organ function labs are not provided and are listed as WNL (within normal limits), further verification is needed.
- It is unclear if the patient has available archival tumor tissue or the willingness to undergo a biopsy.

**Assessment:**
> The patient has renal cell carcinoma that aligns with the trial's focus, has a suitable ECOG status, and has measurable disease and sufficient life expectancy. There are a few uncertainties regarding organ function and availability of tumor tissue, but no major conflicting criteria.

---

### [NCT05703854](https://clinicaltrials.gov/study/NCT05703854)

**Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has advanced clear cell renal cell carcinoma.
- Patient has received at least 1 prior line of therapy for recurrent or metastatic disease, including PD-1 and anti-angiogenic treatment.
- ECOG status is 1.

**? Uncertainties:**
- Need to confirm tumor sample expression of CD70.
- Laboratory results for renal function (creatinine) and hepatic function (ALT, AST) are not provided, though mild hyperbilirubinemia is mentioned.

**Assessment:**
> The patient's disease matches the trial's indication of advanced renal cell carcinoma, and she has prior treatment history as required. However, the expression level of CD70 and specific lab results are needed for full confirmation.

---

### [NCT05700461](https://clinicaltrials.gov/study/NCT05700461)

**Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma**

- **Sponsor**: Wenxin Xu
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Confirmed metastatic renal cell carcinoma
- Patient is 59 years old
- ECOG status is 1
- Patient is medically stable to undergo procedures

**? Uncertainties:**
- Laboratory values related to absolute neutrophil count, platelets, PT (INR), and PTT are not provided
- Extent of disease assessment (CT or MRI) not confirmed if done within required timeframe

**Assessment:**
> The patient's cancer type, age, and ECOG status align with the trial's inclusion criteria. However, laboratory values and the timing of disease assessment could affect eligibility.

---

### [NCT07072234](https://clinicaltrials.gov/study/NCT07072234)

**Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age 59
- ECOG status 1
- Prior therapies include at least one ICI (ipilimumab/nivolumab) and one TKI (cabozantinib, lenvatinib)
- Patient has clear cell renal cell carcinoma (ccRCC)
- Brain metastases: none

**? Uncertainties:**
- Confirmation of CD70 expression â‰¥ 10% by immunohistochemistry staining is required but not provided.
- Absence of specific lab results for renal and hepatic function (hyperbilirubinemia noted at 1.4, needs assessment against the trial limits.)
- Documenting absolute neutrophil count, platelet count, and hemoglobin levels is necessary.

**Assessment:**
> The patient has metastatic clear cell renal cell carcinoma, which matches the trial's indication. The patient has prior systemic therapies that meet the trial's requirement for previously treated patients. While there are some uncertainties regarding biomarker expression and specific lab values, the patient meets most standard eligibility criteria.

---

### [NCT06101290](https://clinicaltrials.gov/study/NCT06101290)

**Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)**

- **Sponsor**: University of California, Davis
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has renal cell carcinoma, which is one of the studied conditions in the trial.
- Patient is 59 years old, meeting the age requirement of â‰¥18 years.
- ECOG status is 1, which is acceptable for most trials.
- Patient has received prior systemic therapy and the current scenario suggests a further line of systemic therapy is ongoing.

**? Uncertainties:**
- The potential for additional locally ablative therapy has not been explicitly stated.
- Details regarding treatment benefit assessment (â‰¥3 months of clinical benefit on most recent line) and the number of new metastatic lesions (should be â‰¤5) are unclear.
- No specific details on medical comorbidities are provided.

**Assessment:**
> The patient's cancer type of renal cell carcinoma aligns with the trial's conditions, and she meets key inclusion criteria such as age and ECOG status. While she has had multiple lines of systemic therapy, which fits the trial's focus on previously treated patients, further details are necessary to confirm criteria related to treatment benefit and number of metastases.

---

### [NCT06910657](https://clinicaltrials.gov/study/NCT06910657)

**A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors**

- **Sponsor**: ViroMissile, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has renal cell carcinoma, which is one of the conditions studied in the trial.
- Patient is 59 years old, meeting the age criteria (â‰¥ 18 years).
- ECOG status is 1, which is acceptable for trial eligibility.
- Patient has advanced renal tumor that has progressed despite prior therapies, indicating previously treated status.

**? Uncertainties:**
- Patient's ability to provide informed consent and comply with study requirements is not explicitly stated.
- Adequate organ function has not been confirmed with lab values, only noted that labs show mild hyperbilirubinemia.
- Extent of measurable disease per RECIST v1.1 not confirmed; it is required for eligibility.

**Assessment:**
> The patient's cancer type aligns with the trial's focus on renal cell carcinoma, and she meets the age and ECOG status criteria. Though she has received multiple lines of prior treatments, the trial allows for previously treated patients, putting her in a potentially eligible category. However, organ function and measurable disease details remain uncertain, slightly decreasing confidence in eligibility.

---

### [NCT06805825](https://clinicaltrials.gov/study/NCT06805825)

**A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit**

- **Sponsor**: Novelty Nobility, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Patient has clear cell renal cell carcinoma, which matches the trial conditions.
- Patient has ECOG status of 1, which meets the trial's requirement.
- Patient is over 18 years old.

**âœ— Potential Conflicts:**
- Patient has prior therapies including ipilimumab, nivolumab, cabozantinib, lenvatinib, and everolimus, but the trial requires patients to be refractory to these standard therapies.

**? Uncertainties:**
- Patient's lab values other than mildly elevated bilirubin were not provided, which may affect eligibility.
- Patientâ€™s organ function labs are not explicitly confirmed.

**Assessment:**
> The patient's cancer type aligns with the trial's focus on clear cell renal cell carcinoma. However, the patient has received multiple prior therapies, which might disqualify her based on the trial's treatment requirement. There are some uncertain factors regarding her organ functions due to missing lab results.

---

## ðŸŸ¡ MEDIUM Likelihood (2 trials)

### [NCT04989959](https://clinicaltrials.gov/study/NCT04989959)

**An Exploratory Study of [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma**

- **Sponsor**: Orhan Kemal Oz
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 66%

**âœ“ Supporting Factors:**
- Patient has metastatic clear cell renal cell carcinoma, which is a condition being studied in the trial.
- Patient has VHL loss, making her potentially eligible for cohort 2.

**âœ— Potential Conflicts:**
- Patient is previously treated, having undergone multiple therapies, whereas trial details suggest a potential focus on treatment-naive patients or specific cohorts requiring prior treatment.

**? Uncertainties:**
- Need verification on whether the trial has specific requirements regarding prior therapies for cohort 2.
- More information is needed to determine eligibility concerning the biopsy requirement for cohort 2.

**Assessment:**
> The patient's cancer type matches the trial study, and she has VHL loss, a relevant biomarker. However, her history of multiple prior therapies raises questions about treatment line eligibility. Thus, there are uncertainties surrounding her eligibility for cohort 2.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Age 59 (â‰¥18)
- ECOG status 1
- Cancer type: renal cell carcinoma (ccRCC)
- Prior therapies: ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus (â‰¥1 prior systemic therapy as required for combination arm)

**âœ— Potential Conflicts:**
- Patient has progressed on cabozantinib (2nd line therapy) which conflicts with the criteria for cabozantinib-naÃ¯ve patients in the eligibility for multiple combination arms.

**? Uncertainties:**
- Acceptable organ function based on available lab results is uncertain.
- Presence of measurable disease per RECIST v1.1 is uncertain.
- Other protocol-defined inclusion and exclusion criteria may apply.

**Assessment:**
> The patient's cancer type matches the study conditions for advanced clear cell renal cell carcinoma. However, the patient has received cabozantinib, disqualifying her for several arms that require cabozantinib-naÃ¯ve patients. Additional criteria must be verified, particularly regarding measurable disease and organ function.

---

## ðŸŸ  LOW Likelihood (5 trials)

### [NCT06234605](https://clinicaltrials.gov/study/NCT06234605)

**A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma**

- **Sponsor**: HiberCell, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 30%

**âœ“ Supporting Factors:**
- Diagnosis of metastatic renal cell carcinoma with a predominant clear cell component

**âœ— Potential Conflicts:**
- Patient has prior therapies (ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus) while the trial does not specify acceptance of previously treated patients.

**Assessment:**
> The patient has a diagnosis of metastatic clear cell renal cell carcinoma, which matches the trial's target indication. However, the patient is not treatment-naive, having received multiple prior therapies, which raises significant doubts regarding eligibility for the trial. Thus, the likelihood of matching is low.

---

### [NCT07043608](https://clinicaltrials.gov/study/NCT07043608)

**A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors**

- **Sponsor**: Kelly Fitzgerald, MD
- **Phase**: Phase 2
- **Status**: Not yet recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years
- ECOG status = 1

**âœ— Potential Conflicts:**
- Patient has renal cell carcinoma, but the trial is limited to patients with bone metastases, and no indication of bone metastases is provided.
- Patient was previously treated with multiple therapies including immune checkpoint inhibitors, while the trial requires 1-3 prior therapies with at least one being an IO therapy without prior treatment with zanzalintinib.

**? Uncertainties:**
- Presence and number of bone metastases which are required for inclusion
- Adequate organ function lab results are not provided

**Assessment:**
> While the patient's age and ECOG status meet some criteria, critical requirements regarding the presence of bone metastases and the treatment prior to the trial are not satisfied, leading to exclusion. Additionally, uncertainties regarding organ function and metastatic status further hinder eligibility assessment.

---

### [NCT06940518](https://clinicaltrials.gov/study/NCT06940518)

**Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Age: 59
- Sex: female
- Cancer type: renal cell carcinoma
- ECOG status: 1
- Prior therapies: ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus
- Brain metastases: none
- Co-mutations: VHL loss
- Country: United States

**âœ— Potential Conflicts:**
- Patient has received prior treatment with cabozantinib, which is a VEGF-directed agent. This conflicts with inclusion criteria for cohort 1 which states that participants must not have received treatment containing a VEGF-directed agent.
- Patient has also received lenvatinib, which is another VEGF-directed agent, further confirming exclusion from cohort 1.
- Patient has progressed on previous treatments, but the trial may require those who have not received certain types of previous treatments for cohort eligibility.

**Assessment:**
> The patient's cancer type matches the trial's indication of metastatic clear cell renal cell carcinoma. However, the patient has received prior treatment containing VEGF-directed agents, specifically cabozantinib and lenvatinib, which conflicts with the inclusion criteria for cohort 1, leading to exclusion.

---

### [NCT04903873](https://clinicaltrials.gov/study/NCT04903873)

**An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors**

- **Sponsor**: Eutilex
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Patient has metastatic clear cell renal cell carcinoma

**âœ— Potential Conflicts:**
- Trial does not include renal cell carcinoma as a specific condition in the Phase 2 indication. Main focus is on colorectal cancer and non-small cell lung cancer.

**? Uncertainties:**
- Patient's overall organ function tests are not provided for thorough evaluation.

**Assessment:**
> The patient's cancer type of renal cell carcinoma does not match the trial criteria as renal cell carcinoma is not explicitly included in the study's conditions for Phase 2, which focus instead on colorectal cancer and non-small cell lung cancer. Given this, the patient is likely excluded.

---

### [NCT05037825](https://clinicaltrials.gov/study/NCT05037825)

**The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors**

- **Sponsor**: VastBiome
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- 59 years old
- female
- diagnosed with renal cell carcinoma

**âœ— Potential Conflicts:**
- patient has prior systemic therapies which may conflict with trial's requirements for treatment-naive
- patient has previously treated disease whereas trial needs previously untreated patients

**? Uncertainties:**
- unknown specific requirements for checkpoint inhibitor treatments in this trial
- uncertainties regarding laboratory values and organ function

**Assessment:**
> The patient's cancer type (renal cell carcinoma) matches the trial condition. However, the patient has multiple prior systemic therapies, suggesting they are not treatment-naive, which may lead to exclusion based on the trial's treatment line eligibility. There are significant uncertainties regarding other eligibility criteria, resulting in a low match likelihood.

---

## Excluded (77 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT03422198](https://clinicaltrials.gov/study/NCT03422198) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04473781](https://clinicaltrials.gov/study/NCT04473781) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04575935](https://clinicaltrials.gov/study/NCT04575935) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04620239](https://clinicaltrials.gov/study/NCT04620239) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04657068](https://clinicaltrials.gov/study/NCT04657068) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04712851](https://clinicaltrials.gov/study/NCT04712851) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04724018](https://clinicaltrials.gov/study/NCT04724018) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04851119](https://clinicaltrials.gov/study/NCT04851119) | Patient age 59 is above maximum age 30 |
| [NCT04919629](https://clinicaltrials.gov/study/NCT04919629) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05064280](https://clinicaltrials.gov/study/NCT05064280) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05256225](https://clinicaltrials.gov/study/NCT05256225) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05267626](https://clinicaltrials.gov/study/NCT05267626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05281471](https://clinicaltrials.gov/study/NCT05281471) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05316155](https://clinicaltrials.gov/study/NCT05316155) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05381597](https://clinicaltrials.gov/study/NCT05381597) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05388773](https://clinicaltrials.gov/study/NCT05388773) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05600777](https://clinicaltrials.gov/study/NCT05600777) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05896839](https://clinicaltrials.gov/study/NCT05896839) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06305767](https://clinicaltrials.gov/study/NCT06305767) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 32 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05663710](https://clinicaltrials.gov/study/NCT05663710) | M.D. Anderson Cancer | Patient is not treatment-naive; has received multiple prior therapies including cabozantinib, which is part of the trial's regimen. |
| [NCT04510597](https://clinicaltrials.gov/study/NCT04510597) | SWOG Cancer Research | Patient has received multiple prior systemic therapies for metastatic renal cell carcinoma, which conflicts with eligibility for previously treated patients in this trial. |
| [NCT03592472](https://clinicaltrials.gov/study/NCT03592472) | Xynomic Pharmaceutic | Patient has had prior treatment with cabozantinib, which is a VEGF tyrosine kinase inhibitor. |
| [NCT05319015](https://clinicaltrials.gov/study/NCT05319015) | University of Texas  | The trial specifically studies patients with renal cell carcinoma with level II-IV inferior vena cava tumor thrombus, and there is no indication in the patient's profile that she has such a thrombus. |
| [NCT06005818](https://clinicaltrials.gov/study/NCT06005818) | University of Alabam | Patient has prior systemic therapy (multiple lines of treatment) while the trial only includes patients who have not received prior systemic therapy for advanced RCC. |
| [NCT06866262](https://clinicaltrials.gov/study/NCT06866262) | University of Michig | Patient has received prior systemic anti-cancer therapy for metastatic disease. |
| [NCT05536141](https://clinicaltrials.gov/study/NCT05536141) | Arcus Biosciences, I | Patient has prior treatment with multiple therapies including cabozantinib and the trial excludes prior treatment with HIF-2Î± inhibitors and cabozantinib. |
| [NCT06966024](https://clinicaltrials.gov/study/NCT06966024) | Deciphera Pharmaceut | Patient has received multiple prior systemic therapies, which may exceed trial's exclusion of previous anticancer therapy. |
| [NCT03972657](https://clinicaltrials.gov/study/NCT03972657) | Regeneron Pharmaceut | Patient has not received an anti-PD-1 therapy (such as cemiplimab) as required in the inclusion criteria for ccRCC cohorts. |
| [NCT04981509](https://clinicaltrials.gov/study/NCT04981509) | National Cancer Inst | Patient has renal cell carcinoma (RCC) which is not a match for the trial that is specifically studying hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell carcinoma. |
| [NCT05641935](https://clinicaltrials.gov/study/NCT05641935) | john eisenbrey | Patient has renal cell carcinoma, but the trial specifically requires patients who have previously received cryotherapy or microwave therapy, which the patient has not. |
| [NCT05269381](https://clinicaltrials.gov/study/NCT05269381) | Mayo Clinic | Patient has already received multiple lines of prior therapies (ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus) which exceeds the trial's requirements for previous treatments. |
| [NCT06500455](https://clinicaltrials.gov/study/NCT06500455) | NRG Oncology | Patient has no intact brain metastases; the trial requires at least 1 intact brain metastasis. |
| [NCT00102544](https://clinicaltrials.gov/study/NCT00102544) | National Institutes  | Patient has renal cell carcinoma but trial mainly studies adenocarcinoma and prostate neoplasms, with renal cell carcinoma indicated but not the primary focus. |
| [NCT04792463](https://clinicaltrials.gov/study/NCT04792463) | Mohamed Abdel-Rahman | Patient has renal cell carcinoma; trial is specifically studying BAP1 hereditary predisposition related to Uveal Melanoma, Cutaneous Melanoma, and other cancers primarily associated with BAP1, but renal cell carcinoma is not the principal focus. |
| [NCT06447103](https://clinicaltrials.gov/study/NCT06447103) | Jonsson Comprehensiv | Patient has metastatic clear cell renal cell carcinoma (ccRCC), while trial is for detecting recurrent ccRCC after surgery. |
| [NCT06794229](https://clinicaltrials.gov/study/NCT06794229) | Qian Qin | Patient has clear cell renal cell carcinoma, but the trial is for locally advanced and/or inoperable clear cell renal cell carcinoma. |
| [NCT06770855](https://clinicaltrials.gov/study/NCT06770855) | Abramson Cancer Cent | Patient has experienced progression after at least 6 months of immune checkpoint blockade therapy, which excludes participation according to exclusion criteria. |
| [NCT07124000](https://clinicaltrials.gov/study/NCT07124000) | AstraZeneca | Patient has renal cell carcinoma, while the trial is designed for HER2-positive tumors. |
| [NCT03786796](https://clinicaltrials.gov/study/NCT03786796) | Sidney Kimmel Compre | Patient has VHL loss but trial requires mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L. |
| ... | ... | *and 5 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| renal cell carcinoma | manual | 1.0 |
| clear cell renal cell carcinoma | llm | 0.9 |
| RCC | llm | 0.8 |
| clear cell carcinoma | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
